These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 7825631)

  • 1. Androgenic effects of oral contraceptives: implications for patient compliance.
    Jones EE
    Am J Med; 1995 Jan; 98(1A):116S-119S. PubMed ID: 7825631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The androgenicity of progestins.
    Darney PD
    Am J Med; 1995 Jan; 98(1A):104S-110S. PubMed ID: 7825629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sex steroids on women's health: implications for practitioners.
    Derman RJ
    Am J Med; 1995 Jan; 98(1A):137S-143S. PubMed ID: 7825634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormonal contraception].
    Van Cauwenberge JR
    Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cutaneous effects in hormonal contraception].
    Thomas P; Dalle E; Revillon B; Delecour M; Devarenne-nicolle MF; Pagniez I
    NPN Med; 1985 Jan; 5(81):19-24. PubMed ID: 12281276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menstrual impact of contraception.
    Stubblefield PG
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1513-22. PubMed ID: 8178900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A; Hahn DW; McGuire JL
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OC practice guidelines: minimizing side effects.
    Darney PD
    Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral contraception: failures and risks].
    Foussard-blanpin O; Paillot-renaud P; Bruneau-bigot A
    Lyon Pharm; 1984 Nov; 35(6):385-93. PubMed ID: 12280590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status.
    Potts M; Denny C
    Drug Saf; 1995 Dec; 13(6):333-7. PubMed ID: 8652077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical aspects of oral contraceptive discontinuation.
    Serfaty D
    Adv Contracept; 1992 Oct; 8 Suppl 1():21-33. PubMed ID: 1442247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.